Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease (Q26747224)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Barbara Toffoli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Fleur Bossi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Bruno Fabris

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

BioMed Research International

6 June 2020

language of work or name

English

0 references

publication date

21 April 2016

7 references

19 June 2019

17 June 2019

31 July 2019

20 November 2019

15 December 2019

19 November 2020

28 October 2022

9 references

19 June 2019

17 June 2019

31 July 2019

20 November 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

19 November 2020

28 October 2022

2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

1752854

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

6 June 2020

copyright license

7 references

19 June 2019

17 June 2019

31 July 2019

20 November 2019

15 December 2019

19 November 2020

on focus list of Wikimedia project

28 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

The receptor for the cytotoxic ligand TRAIL

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Identification and characterization of a new member of the TNF family that induces apoptosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Crosstalk between apoptosis, necrosis and autophagy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Atherosclerosis — An Inflammatory Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Denosumab in postmenopausal women with low bone mineral density

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

A novel receptor for Apo2L/TRAIL contains a truncated death domain

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Apoptosis by death factor

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Global and regional patterns in cardiovascular mortality from 1990 to 2013.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin in Cardiometabolic Disorders

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

The role of osteoprotegerin in cardiovascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

State of art and recent developments of anti-cancer strategies based on TRAIL.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Inflammation, kidney function and albuminuria in the Framingham Offspring cohort

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

RANK, RANKL and osteoprotegerin in bone biology and disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Role of full-length osteoprotegerin in tumor cell biology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

To kill a tumor cell: the potential of proapoptotic receptor agonists

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Expression, regulation and function of trail in atherosclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Expression and regulation of osteoprotegerin in adipose tissue

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Mouse models for atherosclerosis and pharmaceutical modifiers.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Safety and antitumor activity of recombinant soluble Apo2 ligand

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin is up-regulated in pancreatic cancers and correlates with cancer-associated new-onset diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

31 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipid rafts are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Association of osteoprotegerin with human abdominal aortic aneurysm progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Prognostic value of apoptosis markers in advanced heart failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

TRAIL shows potential cardioprotective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Phosphatidylinositol 3-kinase/Akt pathway regulates inflammatory mediators-induced calcification of human vascular smooth muscle cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4856888

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

28 November 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F1752854

Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure

21 January 2018

1 reference

12 December 2020

Assessment of a serum assay for quantification of abdominal aortic calcification

1 reference

12 December 2020

Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice

1 reference

12 December 2020

Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes

1 reference

12 December 2020

Increased osteoprotegerin serum levels in men with coronary artery disease

1 reference

12 December 2020

The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients

1 reference

12 December 2020

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects

1 reference

12 December 2020

Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis

1 reference

12 December 2020

Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study

1 reference

12 December 2020

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids

1 reference

12 December 2020

Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects

1 reference

12 December 2020

Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor

1 reference

12 December 2020

Accelerated atherosclerosis in prolonged maintenance hemodialysis

1 reference

12 December 2020

TRAIL expression in vascular smooth muscle

1 reference

12 December 2020

Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification

1 reference

12 December 2020

Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure

1 reference

12 December 2020

PI-3K/Akt and NF-?B/I?B? pathways are activated in Jurkat T cells in response to TRAIL treatment

1 reference

12 December 2020

Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease

1 reference

12 December 2020

Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway

1 reference

12 December 2020

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

1 reference

12 December 2020

1 reference

12 December 2020

Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes

1 reference

12 December 2020

Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells

1 reference

12 December 2020

PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways

1 reference

12 December 2020

Identifiers

DOI

10.1155/2016/1752854

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27200369%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

PubMed publication ID

27200369

2 references